near-term support thesi
overal proprietari survey suggest ms franchis could
face broad-headwind near-term part recent initi coverag
noth come noth pipelin concern remain
aducanumab failur conduct survey physician better
understand dynam ms market current leader
ms think challeng like across segment includ inject
avonex/ plegridi oral tecfidera iv tysabri whole translat
believ higher expect eros ms franchis cs
year compound-annual-growth-rate consensu highlight biogen increasingli
urgent need transact secur revenu growth near-term reiter
under-perform tp
oral ms franchis could face headwind competit emerg
vumer unlik panacea franchis among oral
tecfidera led class report usag expect howev
better oral becom avail could see eros class expect
conveni minim invas rel favor payer support
oral therapi mitig eros ocrevu particularli treatment-nav
anticip prefer oral persist launch
vumer potenti enhanc toler could creat opportun
vumer serv commerci successor tecfiderastil physician
awar low suggest slow uptak could also see eros
tecfidera even vumer gener oral gilenya
aubagio launch us expect respect
challeng patent add anoth layer risk franchis
host confer call today et review survey
find ms physician dial-in us
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc biopharmaceut compani engag
discov develop deliv therapi neurolog
neurodegen diseas
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
experi greater expect degre eros
competit eros occur partial off-set sale
vumer spinraza remain standard care sma
risdiplam zolgensma either fail clinic take
meaning share share repurchas lead meaning
accret constant improv multipl
grey scenario assum ms franchis declin
greater expect rate new therapi take greater
expect share near-term zolgensma captur major
new incid sma market long-term spinraza lose share
risdiplam preval sma market capit
deploy strategi fail gener meaning earn growth
share experi even greater degre multipl
 close
treatment-nav usag ocrevu increasingli like use
treatment-experienc patient like expens biogen tysabri despit
indic increas willing use report histor ocrevu usag
treatment-nav case respond plan increas usag first
therapeut switch mani expect decreas usag inject therapi
follow year see figur think trend would impact biogen
tysabri model comprehens ms model iv therapi
receiv royalti ocrevu believ
enough off-set tysabri revenu eros use inject therapi interferon
copaxon etc also like declin time account interferon
forecast five-year compound-annual-growth-rate
figur anticip one-year chang prescript habit patient first switch
time expect continu crowd market bolster novel asset
oral novartiss mayzent celgen ozanimod iv roch
ocrevu space also concern approv vumer alter
trajectori oral market point crowd less prescrib familiar
survey bright spot could number ms patient
continu increas benefit blunt competit increas
follow key take-away survey support thesi ms busi
physician satisfact ocrevu high increasingli attract option
potenti expens tysabri older-iv therapi
ocrevu usag treatment-nav set remain low patient start
ocrevu good oral whole solv crowd issu
tecfidera seem stabl near term competit oral segment
could hamper usag vumer low awar could blunt launch
compani mention price
